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Pendahuluan: Rawatan terapi penggantian hormon (TPH) sering di beri kepada wanita 
menopaus untuk mengurangkan gejala vasomotor. Pengunaan TPH bagi wanita menopaus 
disabitkan dengan peningkatan ketumpatan pada mammogram dan juga kesan kesakitan pada 
payudara. Ketumpatan mammogram adalah salah satu risiko yang mengakibatkan kanser 
payudara. 
 
Tujuan: Tujuan kajian ini adalah untuk menguji kesan TPH terhadap ketumpatan 
mammogram. 
 
Metodologi: Satu kajian pemerhatian telah dijalankan selama 18 bulan. Seramai 33 
wanita yang telah menopaus dan menerima rawatan TPH telah direkrut untuk kajian ini. 
Prosedur mammogram telah dijalankan sebelum rawatan dimulakan and selepas 12 bulan 
menerima TPH. Mammogram telah dikaji dan diselidik dengan menggunakan cara klassifikasi 
BIRADS. Wanita tersebut juga telah ditemuramah tentang pengalaman kesakitan pada payudara 
dengan menggunakan skala yang telah ditetapkan. 
 
Keputusan: Perubahan yang ketara dari segi statistik telah direkodkan dengan kajian 
secara kategorikal seperti cara klassifikasi BIRADS. Terdapat 30.3% wanita yang mempunyai 
penambahan ketumpatan mammogram dan 33.3% wanita yang mengadu kesakitan payudara 
selepas menerima rawatan TPH. Perubahan yang ketara dari segi statistik telah direkodkan antara 
kesakitan payudara selepas rawatan TPH dan penambahan ketumpatan mammogram. Kami juga 
membuat kesimpulan bahawa fakto-faktor lain seperti umur, jumlah anak, indeks jisim badan, 
umur sewaktu putus haid dan tempoh putus haid tidak berkait secara statistik dengan 
peningkatan ketumpatan mammogram.  
 
Kesimpulan: Kajian ini menunjukkan bahawa rawatan TPH menunjukkan perkaitan 
yang ketara dengan ketumpatan mammogram. Seramai 30.3% wanita yang menerima rawatan 
TPH didapati mempunyai peningkatan ketumpatan mammogram. Seramai 33.3% wanita yang 
menerima TPH mengadu kesakitan pada payudara. Peningkatan ketumpatan mammogram juga 
didapati berkait rapat dengan kesakitan pada payudara di kalangan wanita yang menerima 
rawatan TPH. 
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Introduction: Hormone replacement therapy (HRT) is commonly prescribed to 
postmenopausal women to improve their postmenopausal symptoms. Postmenopausal hormone 
use is associated with increase in mammographic density and increased incidence of breast pain. 
Mammographic density is an independent risk factor for breast cancer. 
 
Objective: Our purpose was to evaluate the effects of hormone replacement therapy on 
mammographic density in postmenopausal women in Kota Bharu, Kelantan, Malaysia. 
 
Material and Method: An observational study was conducted for a period of 18 months. 
A total of 33 postmenopausal women who received combined hormone replacement therapy 
(containing estrogen and progesterone) were included as study subjects. Mammograms were 
performed at baseline and after 12 months of receiving HRT. Mammographic density was 
evaluated according to BIRADS classification of breast density. During follow-up, patients were 
also enquired about breast pain and they were asked to classify according to a specified scale. 
 
Result: The categorical assessments showed that there was a significant shift in 
categorical classification as assessed by BIRADS categories among the postmenopausal women 
receiving hormone replacement therapy. Amongst these women, 30.3% had increased 
mammographic density after treatment with HRT. There was also significant association 
between breast pain and increase in mammographic density. Amongst the study population, 
33.3% complained of breast pain after hormonal therapy. We also concluded that the study 
factors (grade, age, parity, BMI, duration of menopause and age at menopause) did not 
significantly influence change in mammographic density. 
 
Conclusion: Hormone replacement therapy significantly affects the mammographic 
density and increased mammographic density was associated with breast pain in women 
receiving hormonal therapy. 
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Abstrak (Versi Bahasa Malaysia)  
Pendahuluan 
Rawatan terapi penggantian hormon (TPH) sering di beri kepada wanita menopaus 
untuk mengurangkan gejala vasomotor. Pengunaan TPH bagi wanita menopaus 
disabitkan dengan peningkatan ketumpatan pada mammogram dan juga kesan kesakitan 
pada payudara. Ketumpatan mammogram adalah salah satu risiko yang mengakibatkan 
kanser payudara. 
 
Tujuan 
Tujuan kajian ini adalah untuk menguji kesan TPH terhadap ketumpatan mammogram. 
 
Metodologi 
Satu kajian pemerhatian telah dijalankan selama 18 bulan. Seramai 33 wanita yang 
telah menopaus dan menerima rawatan TPH telah direkrut untuk kajian ini. Prosedur 
mammogram telah dijalankan sebelum rawatan dimulakan and selepas 12 bulan 
menerima TPH. Mammogram telah dikaji dan diselidik dengan menggunakan cara 
klassifikasi BIRADS. Wanita tersebut juga telah ditemuramah tentang pengalaman 
kesakitan pada payudara dengan menggunakan skala yang telah ditetapkan. 
 
Keputusan 
Perubahan yang ketara dari segi statistik telah direkodkan dengan kajian secara 
kategorikal seperti cara klassifikasi BIRADS. Terdapat 30.3% wanita yang mempunyai 
penambahan ketumpatan mammogram dan 33.3% wanita yang mengadu kesakitan 
payudara selepas menerima rawatan TPH. Perubahan yang ketara dari segi statistik 
telah direkodkan antara kesakitan payudara selepas rawatan TPH dan penambahan 
 xii 
 
ketumpatan mammogram. Kami juga membuat kesimpulan bahawa fakto-faktor lain 
seperti umur, jumlah anak, indeks jisim badan, umur sewaktu putus haid dan tempoh 
putus haid tidak berkait secara statistik dengan peningkatan ketumpatan mammogram.  
 
Kesimpulan  
Kajian ini menunjukkan bahawa rawatan TPH menunjukkan perkaitan yang ketara 
dengan ketumpatan mammogram. Seramai 30.3% wanita yang menerima rawatan TPH 
didapati mempunyai peningkatan ketumpatan mammogram. Seramai 33.3% wanita 
yang menerima TPH mengadu kesakitan pada payudara. Peningkatan ketumpatan 
mammogram juga didapati berkait rapat dengan kesakitan pada payudara di kalangan 
wanita yang menerima rawatan TPH. 
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Abstract (English Version) 
Introduction 
Hormone replacement therapy (HRT) is commonly prescribed to postmenopausal 
women to improve their postmenopausal symptoms. Postmenopausal hormone use is 
associated with increase in mammographic density and increased incidence of breast 
pain. Mammographic density is an independent risk factor for breast cancer. 
 
Objective 
Our purpose was to evaluate the effects of hormone replacement therapy on 
mammographic density in postmenopausal women in Kota Bharu, Kelantan, Malaysia. 
 
Material and Method 
An observational study was conducted for a period of 18 months. A total of 33 
postmenopausal women who received combined hormone replacement therapy 
(containing estrogen and progesterone) were included as study subjects. Mammograms 
were performed at baseline and after 12 months of receiving HRT. Mammographic 
density was evaluated according to BIRADS classification of breast density. During 
follow-up, patients were also enquired about breast pain and they were asked to classify 
according to a specified scale. 
 
Result 
The categorical assessments showed that there was a significant shift in categorical 
classification as assessed by BIRADS categories among the postmenopausal women 
receiving hormone replacement therapy. Amongst these women, 30.3% had increased 
mammographic density after treatment with HRT. There was also significant 
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association between breast pain and increase in mammographic density. Amongst the 
study population, 33.3% complained of breast pain after hormonal therapy. We also 
concluded that the study factors (grade, age, parity, BMI, duration of menopause and 
age at menopause) did not significantly influence change in mammographic density. 
 
Conclusion 
Hormone replacement therapy significantly affects the mammographic density and 
increased mammographic density was associated with breast pain in women receiving 
hormonal therapy. 
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1.0 Introduction 
Menopause is a state of natural ovarian senescence with accompanying oestrogen 
deficiency. It also refers to states of ovarian failure and ovarian destruction/removal 
with accompanying oestrogen deficiency. Natural menopause is recognized to have 
occurred after 12 consecutive months of amenorrhoea for which there is no other 
obvious pathological or physiological cause. Menopause is a universal and irreversible 
part of the overall aging process involving a woman’s reproductive system.  
 
The life span of women has improved significantly in the last two decades. Malaysian 
women’s life expectancy now has reached 76.4 years and for male it is 70.6 years 
(Department of Statistics Malaysia, 2005). However, the age of onset of menopause has 
not changed and remained at 50 to 52 years despite improvement in life expectancy of 
women. This means women will spend nearly one third of their life span in the 
postmenopausal years. Failure of estrogen production by the ovaries during this period 
can lead to various changes in their bodies. These changes can be constituted into: 
• Early menopause symptoms such as vasomotor instability and psychosexual 
disturbances 
• Late menopause symptoms such as osteoporosis and heart disease 
 
Hormone replacement therapy (HRT) remains the first-line and most effective treatment 
for menopausal symptoms. However, despite massive, good-quality clinical outcome 
data on efficacy and safety when HRT is begun for symptoms in the early menopause, 
many physicians and lay people believe that hormones are risky and undesired even in 
the most appropriate case scenarios. Many misconceptions and misperceptions play 
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roles in this complicated situation, some are purely scientific whereas others are cultural 
or social (Pines, A. et al., 2007). 
 
Prolonged administration of HRT has been associated with a slight but statistically 
significant increase in the risk of breast cancer. HRT slows normal breast involution and 
can cause an increase in mammographic density. There have been various studies on the 
interplay between HRT and breast density. HRT causes increase in mammographic 
density in up to 25% of women. This increase in density is largely determined by the 
preparation of HRT and likely to follow prolonged use and use before menopause 
(Warren, R. 2004).  
 
Mammographic density is one of the parameters evaluated in the mammogram and is 
best determined by the relative amounts of epithelial tissue, connective tissue and fat in 
the breast. All non fatty breast tissue e.g. epithelial tissue and connective tissue will 
appear as white on mammogram and referred to as mammographic densities. The extent 
of breast density varies widely among women but in general decreases with age 
especially after menopause (Laya et al., 1995). 
 
The amount of dense tissue in the breast can be assessed either categorically or 
continuously. Wolfe J. N. was the first to describe four categorical patterns of 
mammographic density. There are various other methods to classify the mammographic 
density. Mammographic density has two important implications. A dense parenchymal 
pattern may be a predictor of breast cancer risk and the density may affect 
mammographic sensitivity (Leung, w. et al., 1997). 
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The hormonal environment in which breast cancer develops appears to be revealed by 
observing mammographic density (Warren, R. 2004). Breast cancer is the commonest 
cancer for females in Malaysia, with a prevalence of 86.2 per 100,000 women in 1996. 
Breast cancer mortality rate shows an increasing trend in Malaysia from 0.61 in 1983 to 
1.8 per 100,000 women in 1992. Based on the report from the Malaysian National 
Cancer Registry (NCR) 2003, breast cancer was the commonest cancer in all ethnic 
groups and all age groups in females from the age of 15 years. The overall age-
standardized rate (ASR) was 46.2 per 100,000 populations.  
 
Risk of developing breast cancer is higher among women 50 years and above. Normal 
ovarian activity increases the risk of breast cancer. An early menarche increases the risk 
before age 35 years, and a late menopause increases the risk later in life. 
 
Breast pain is common and affects 50 - 70% of all women at some time in their lives. 
There are different types and patterns of breast pain which normally relate to the 
underlying cause. The most common pattern is cyclical breast pain which means it 
shows a definite relationship to the menstrual cycle, almost always pre-menstrual, with 
a duration varying from a few days, up to four weeks. Another common cause of breast 
pain is medication containing hormones in them, either contraceptive pills or hormone 
replacement therapy. 
 
Breast pain is a common side effect of hormone replacement therapy. This is usually 
attributable to the oestrogen component of the therapy. HRT may cause transient breast 
tenderness, especially in older women and those furthest from the menopause. Results 
of the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial and other 
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randomized controlled trials demonstrate that breast discomfort increases with 
administration of combined oestrogen and progestin therapy. Postmenopausal women 
who experience new pain in their breasts while taking hormone replacement therapy 
may have an increased risk of developing breast cancer. The researchers concluded that 
new onset breast pain while taking hormone replacement therapy is associated with an 
increase in breast tissue density. Since breast tissue density is associated with an 
increased risk of breast cancer, these results indicate that new onset breast pain may 
ultimately be associated with an increased risk of breast cancer among postmenopausal 
women taking hormone replacement therapy. 
 
Knowing the above mentioned risks, this study was designed to determine if HRT 
increases the mammographic density in postmenopausal women and to assess the 
incidence of increased breast density in postmenopausal women receiving HRT.  Many 
studies have been done in Western countries on effect of HRT on mammographic 
density but not many similar studies have been done locally. Mammographic density is 
an independent risk factor for breast cancer. The degree of risk that is associated with 
mammographic density is greater than the degree of risk that is associated with almost 
all other known breast cancer risk factors. Knowledge of the variables associated with 
increased mammographic density may allow greater understanding of the nature and 
causes of breast cancer. As a result, measurement of mammographic density is useful as 
a mean of investigating the etiology of breast cancer and to test the hypotheses about 
potential strategies. 
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2.0 Literature Review 
2.1 Mammary gland 
 
The mammary glands are modified skin gland enveloped in fibrous fascia (Moore, K. L. 
2005). Mammary gland develops on the chest wall between the clavicle and the sixth to 
eight ribs. It develops under the influence of estrogens in adolescence to reach its adult 
size. There are fifteen to twenty lobes in each breast disposed radially around nipple. 
Each lobule is composed of grape-like clusters of acini (also called alveoli), the hollow 
sacs that make and hold breast milk. The mammary gland is made up of both fatty tissue 
and glandular milk-producing tissues (Dahnert, W. 2000). 
 
Most breast cancer is thought to originate in the terminal ductal lobular unit (TDLU). 
The gland is anchored to the pectoralis major fascia by the suspensory ligaments first 
described by Astley Cooper in 1840. These ligaments run throughout the breast tissue 
parenchyma from the deep fascia beneath the breast and attach to the dermis of the skin. 
Lobes, lobules, and acini serve to produce and secrete milk—the primary function of the 
breast mammary glands. 
 
Mammary glands receive its blood supply from several sources. The arteries are mainly 
from the internal thoracic artery via its perforating branches, which pierce the second to 
fourth intercostals spaces. There is also supply from the axillary artery mainly from its 
lateral thoracic and thoracoacromial branches as well as the intercostals arteries. The 
veins correspond to the arteries. The chief venous drainage is to the axillary vein 
(Moore, K. L. 2005). 
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The lymphatic system of the breast is of clinical importance in terms of cancerous 
spread. Lymphatic drainage is primarily via the axilla (97%) with the internal mammary 
chain accounting for the remaining 3%. The lateral quadrants of the breast drain into the 
anterior axillary or pectoral nodes. The medial quadrant drains into the nodes along the 
internal thoracic artery. A few lymph vessels follow the posterior intercostals arteries 
and drain posteriorly into the posterior intercostals nodes. Some lymphatic vessels 
communicate with the lymph vessels of the opposite breast (Moore, K. L. 2005) 
 
2.2 Factors affecting breast tissue composition 
 
Glandular tissue and fat vary with a woman's age and weight. The ratio of fatty tissue to 
glandular tissue varies among individuals. In addition, with the onset of menopause, the 
relative amount of fatty tissue increases as the glandular tissue diminishes. Increased or 
decreased glandularity of the breast is a part of the normal physiologic process changes 
that take place within the breast and is generally mirrored on the opposite breast. It can 
be related to hormonal fluctuation (whether normal or synthetic) including menarche, 
pregnancy, lactation or menopause. Increase in glandularity is also dependent on a 
woman’s genetic predisposition. Although the breast is fully developed by age 20, 
complete maturation of the breast may not occur until the woman reaches 30 years 
(Peart, O. J. 2005). The two most important hormones active in breast development are 
estrogen and progesterone. Estrogen is responsible for ductal proliferation whereas 
progesterone is responsible for lobular proliferation and growth. 
 
The mature breast undergoes cyclic changes during the menstrual cycle. Estrogen 
increases cell proliferation and progesterone enhances this effect. During the follicular 
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phase, cell proliferation increases and is further enhanced during the luteal phase. On 
mammograms, these changes are reflected by greater breast density during the luteal 
phase than during the follicular phase. As women near menopause, the menstrual cycle 
shortens. Specifically, the follicular phase shortens, with no significant change in the 
length of the luteal phase. With the reduction of estrogen and progesterone levels after 
menopause, the cyclic proliferative process becomes quiescent. Lobular tissue 
regresses, while the more proximal portions of the ductal system remain. The 
mammographic appearance of the breasts becomes increasingly radiolucent, with about 
34% of women aged 75–79 years having fat-replaced breasts compared with only 11% 
of women aged 25–29 years (Jennifer A. H. and Victor E. B. 2004). 
 
2.3 Mammography 
2.3.1 Mammogram 
 
A mammogram is the x ray of the breast made with specific x-ray equipment. A 
mammogram is the best radiographic method available today to detect breast cancer 
early. It is ideal and indispensable for women older than 40 years, for whom the risk of 
breast cancer is increased. The acceptable physical criteria for optimal mammogram are 
mean optical density of 1.4 to 1.8, high spatial resolution of 10 line pairs per mm, low 
contrast spatial resolution of 3.2 line pairs per mm and mean glandular dose of 2mGy 
per view. 
 
The technical requirements for screen-film mammography differ considerable from 
those for other radiographic studies. Dedicated mammography x-ray equipment is 
necessary for producing high quality images. Since it contains a phosphor which 
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converts x-ray energy into light, a screen-film system allows a lower dose than obtained 
with film alone. The most commonly used target filter combination is a molybdenum 
target with 0.03mm Mo filter. Soft tissue contrast depends on a relatively low kVp x-ray 
beam to enhance the differential absorption of fatty, fibroglandular and calcific tissues. 
The peak kilovoltage is normally in the range of 26 – 30 kV and typically 28 kV. The 
resultant x ray spectrum exhibits characteristic x rays at 17.4 and 19.4 keV. High 
resolution is needed to visualize microcalcifications and trabeculae, often as small as 
0.1mm. Short exposure times are necessary to prevent motion unsharpness. The focus to 
film distance is in the range of 60 – 65mm. 
 
Automatic exposure control (AEC) is used in mammography to automatically control 
the exposure duration so that the optimum optical density of the mammogram is 
maintained over a wide range of different breast sizes and densities. Moving grid 
system is used in mammography to improve resolution and contrast by decreasing 
scattered radiation.  
 
Breast compression is essential to ensure high quality mammograms and is applied 
using a powered system operated by a foot control. Film compression should be applied 
to the entire breast. The purpose of even and firm compression is to geometric 
unsharpness, improve contrast by reducing scatter, diminish motion unsharpness, to 
reduce radiation dose, to achieve more uniform film density and to separate 
superimposed breast tissues so that lesions are better seen.  
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2.3.2 Mammography projections 
 
The standard screen-film mammographic examination consists of a medial-lateral 
oblique (MLO) and cranio-caudal (CC) view of each breast. Careful positioning is 
essential for optimal demonstration of breast tissue. 
 
The standard CC view is obtained with a vertical x-ray beam and the breast being 
compressed between the two plates horizontally. The CC view demonstrates the 
subareolar, medial and lateral portion of the breast. However, the posterolateral aspect 
of the breast may be incompletely demonstrated. The antero-posterior distance of the 
breast should be within 1cm of the length of posterior nipple line. Posterior nipple line 
is the perpendicular distance from the back of the nipple to the anterior margin of the 
pectoral muscle on MLO view. 
 
The medial-lateral oblique view is usually obtained with the x ray tube angled between 
30 – 60 degrees to the horizontal depending on the built and pectoralis muscle of the 
women. This is to ensure compression is applied perpendicular to the long axis of the 
pectoralis muscle. More breast tissue is demonstrated in MLO view than any other 
views. The nipple should be in profile in MLO view. The pectoralis muscle should be 
visible down to the level of the nipple, and the axillary tail and inframammary fold 
should be visible. The breast should not be sagging. The glandular tissue should be 
evenly compressed and adequately penetrated. There should be no skin folds 
superimposed on the breast. Patients need to be relaxed to achieve satisfactory 
positioning. 
 
 - 10 - 
 
Supplemental views are occasionally obtained to further evaluate the breast tissue. 
Magnification views are obtained by increasing the object-film distance to produce an 
air gap and a fine focal spot is used to increase resolution. A magnification factor of 1.5 
is usual and the increased resolution obtained is particularly helpful for detailed analysis 
of microcalcification and margin of small mass lesions. Localized compression views 
are obtained by using a small paddle compression device. This is to displace the 
overlying breast tissue so that better demonstration of the features of the lesion can be 
obtained. 
 
2.4 Mammographic Density 
 
The tissues of the breast are seen on mammogram in three levels of density – fatty 
tissue that is lucent, tissues of water density and calcifications (Warren, R. 2004). 
Fibroglandular tissue is a mixture of fibrous connective tissue and glandular tissue. The 
tissues of water density comprise glandular tissues which are ductal elements, vessels, 
stroma and Cooper’s ligaments. The degree of density varies between individuals. Fat 
appear darker on mammogram because it is more radiolucent than fibroglandular tissue. 
Fibroglandular tissue appears as radio-opaque area and often referred as mammographic 
density or breast density (Byng et al., 1996). 
 
There are wide ranges of breast appearances on mammogram due to variation in breast 
compositions. The mammographic picture of the breast varies between women 
according to the relative amount of fat, connective and epithelial tissues. High amounts 
of connective and epithelial cells yield an increased density in the mammogram. 
Variations in mammographic density are associated with ovarian function. Density is 
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increased in women with an early menarche and also during the luteal phase of the 
menstrual cycle (Soderqvist G. and Schoultz v. B. 2004). Breast parenchymal density in 
individual women has also been found to vary with age, menopausal status, parity, 
height and body weight.  
 
With the reduction of estrogen and progesterone levels after menopause, the lobular 
tissue regresses. As a result, breasts will appear more radiolucent on mammogram. The 
breast will continue to become less dense with about 50% of women in their 40s and 
65% of women in their 20s have 50% or greater breast density (Stomper et al., 1990). 
 
2.5 Methods of measuring mammographic density 
 
There are many ways to assess the mammographic density, both qualitative and 
quantitative. Qualitatively the breast parenchyma can be classified using Wolfe, Laszlo 
Tabar and BIRADS methods. Semi-quantitative assessment was done by Boyd et al., 
1992 which was based on visual estimation of the percentage of the breast occupied by 
breast tissue. Quantitative measurement can be made by computer-aided method (Chow 
et al., 2000). A number of investigators are trying to devise a means of determining the 
total glandular content from three-dimensional reconstruction of breast (Shephard J. and 
Bopp J. 2002). Other investigators are exploring the use of magnetic resonance imaging 
and ultrasonography for quantifying breast density, although these methods may not 
prove as useful for widespread use as density information already obtained on the 
mammogram (Jennifer A. H. and Victor E. B. 2004). 
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2.5.1 Wolfe Classification 
 
In 1976, Wolfe devised a system of classification of mammograms, based on the extent 
and pattern of radiologically dense tissue. He classified breast parenchyma on 
mammogram into four categories based on radiographic appearance (Wolfe J. N. 1976). 
Wolfe parenchymal pattern is based not only on extent of the densities but also on the 
characteristics of the densities seen (prominent ducts and dysplasia). The following are 
the description provided by Wolfe.  
• N1 category refers to the parenchyma composed primarily of fat at most small 
amounts of dysplasia and no ducts are visible.  
• P1 category refers to parenchyma composed chiefly of fat with prominent ducts 
in the anterior portion up to the one-fourth the volume of the breast.  
• P2 category indicated severe involvement of the breast with prominent ductal 
patterns occupying more than one-fourth the volume of breast.  
• DY category refers to severe involvement with dysplasia often obscures an 
underlying prominent ductal pattern.  
 
Nulliparous women and women with family history of breast cancer are those most 
likely to fall into the P2 and DY categories (Ernster et al., 1980). This classification has 
been applied inconsistently and has wide range of interobserver agreement. In a 1993 
review, (Oza and Boyd., 1993) found that the Wolfe classification had an interobserver 
agreement of 52%–97% and an intraobserver agreement of 69%–97% (Oza and Boyd, 
1993). 
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2.5.2 Laszlo Tabar Classification 
 
Laszlo Tabar developed a method of classification based on anatomic-mammographic 
correlation. There are five patterns in this classification.  
• Pattern I involve scalloped contours from Cooper’s ligaments and evenly 
scattered terminal ductal lobular units (TDLU) as 1-2 mm nodular densities on 
the mammogram. There are also oval shaped lucent areas corresponding to fatty 
replacement in this pattern. 
• Pattern II represents complete fatty replacement of the breast.  
• Pattern III is the combination of retroareolar prominent duct pattern due to 
periductal elastosis and fatty involution.  
• Pattern IV demonstrates extensive nodular and linear densities throughout the 
breast. The linear densities are due to periductal elastic tissue proliferation with 
fibrosis called fibroadenosis. The scattered nodular densities of 3-7mm are due 
to proliferating glandular structures and enlarged TDLU referred as adenosis.  
• Pattern V consists of homogeneous, uniformly dense parenchyma with smooth 
contour due to extensive fibrosis.  
 
In terms of risk of developing breast cancer, patterns I to II are considered as low risk 
group and patterns IV and V are considered as high risk group. 
 
Gram et al reported that the overall agreement on high risk versus low risk for Tabar 
and Wolfe classification was 55% with k value of 0.23. This indicates a poor agreement 
between these two classifications (Gram I. T., Funkhouser E. and Tabar L. 1997). The 
study also showed that the strength of association between high risk mammographic 
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patterns and the three selected breast cancer risk factors e.g. parity, number of children 
and age at first birth, was of greater magnitude when the Tabar instead of the Wolfe 
classification was applied. Tabar classification also appears to be more closely related to 
breast cancer risk factors among perimenopausal women compared to Wolfe 
classification. 
 
2.5.3 BIRADS Density Categories 
 
In the United States, Breast Imaging Reporting and Data System (BIRADS) is used in 
mammographic reporting to standardize mammography reporting terminology and 
recommendation categories. Density classification is also included in the BIRADS 
reporting to inform referring physicians of the decline of sensitivity of mammography 
with increasing breast density. The four categories used in the BIRADS are almost 
entirely fatty, scattered fibroglandular densities, heterogeneous density and extremely 
dense. The advantage of BIRADS is that it is used by practicing radiologists. PEPI trial 
found that they were highy reliable with inter-observer agreement ranging from 70% to 
90%. 
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Figure 5-1 Mammography based on BIRADS classification 
(Adapted from Interactive Mammography Analysis Web Tutorial – Internet) 
 
2.5.4 Percentage categories 
 
Visual estimation of the percentage of the breast occupied by the fibroglandular tissue 
has been used frequently. In a study conducted by Stomper et al, parenchymal density 
on mammogram was assessed visually and was categorized as less than 10%, 10% - 
49%, 50% - 89% and 90% or greater dense tissue. The subcutaneous and retromammary 
fat regions in each breast were excluded during the determination of dense tissue. In 
patient with asymmetric tissue, the breast with greater density was categorized (Stomper 
et al., 1996). 
 
Boyd et al proposed a five categories systems which are <10%, 10% - 25 %, 25% - 
50%, 50% - 75% and ≥75%. In this study, the reliability of this classification was 
assessed by rereading 100 images. Boyd reported intraclass correlation coefficient of 
0.94 for repeated reading. This indicates high degree of reliability (Boyd et al., 1995). 
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2.5.5 Radiographic method 
 
Breast glandularity could also be determined from radiographic data e.g. tube potential 
(kV), tube loading (mAs) and compressed breast thickness. Radiographic data was 
collected by exposing different thickness of phantom material of varying glandular and 
adipose compositions at 27 kV. Then a fitted equation was derived and applied to 
calculate breast glandularity. In the study conducted by Jamal at al using this method, 
the average breast glandularity of Malaysian women was 48.9% (Jamal et al., 2004). 
 
 2.6 Hormone replacement therapy (HRT) 
 
The preventive effect of HRT on postmenopausal bone loss and cardiovascular disease 
as well as alleviating effect on climacteric symptoms is well established (Ozdemir et al., 
1999). Clinical trials consistently demonstrate that HRT effectively relieves menopausal 
symptoms in most women and provides clinically significant long-term beneficial 
effects as well (Rozenberg, S. 2001). Many different hormone regimens are used 
including estrogen, estrogen in cyclic combination with a progestogen and estrogen in 
continuous combination with a progestogen (Topal et al., 2006). Current HRT regimens 
combine continuous estrogen with continuous or sequential progestogen to achieve the 
beneficial effects of estrogen while avoiding the increased risk of endometrial cancer. 
Placebo controlled studies have shown that estrogen is effective for post menopausal 
vasomotor and urogenital symptoms (Drife, 2005). Estrogen only therapy is only 
recommended for women without a uterus.  
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Traditional HRT regimes of continuous estrogen and either continuous or sequential 
progesterone are sometimes associated with troublesome progesterone-related side 
effects, which may cause women to stop treatment before long-term beneficial effects 
on osteoporosis or cardiovascular disease can be realized (Breckwoldt M., Keck C. amd 
Karck U. 1995). The major reasons for early discontinuation and low patient 
compliance with HRT include the fear of cancer, the return of menstrual bleeding with 
sequential regimen and also occurrence of premenstrual syndrome-like symptoms 
(Rozenberg, 2001). 
 
Controversies about the safety of different postmenopausal hormone therapies started 
30 years ago and reached a peak in 2003 after the publication of results from the 
Women Health Initiative (WHI) trial and the Million Women Study (MWS) (Topal, N 
et al., 2006). WHI study found increased risks of venous thromboembolism, 
cardiovascular disease, stroke and breast cancer with the use of continuous conjugated 
oral estrogen with medroxyprogesterone acetate (MPA). The limitations of the trial who 
studied 16,000 postmenopausal women are that they included older women who were 
postmenopausal for many years whose results may not extrapolate to a younger 
menopausal woman (Dull, P. 2006). Million Women Study studied the prevalence of 
breast and uterine malignancies among users and non users on HRT. The study revealed 
an increased risk of breast cancer with long term therapy of estrogen (Dull, P. 2006).  
 
In light of the findings of these large scale studies, concerns were raised about the safety 
of HRT use and this caused anxiety and concern to both medical professionals and the 
public. There is currently consensus that HRT is justified for the relief of symptoms but 
not for the prevention of chronic disease after the menopause (Drife, J. 2005). The 
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College of Obstetricians & Gynaecologists and Academy of Medicine of Malaysia 
produced an updated Clinical Practice Guidelines (CPG) in July 2010 which 
recommends that initiation of HRT should be done in relation to proximity to 
menopause. Thus, it is best to start HRT between the ages of 50-59 years, or within 10 
years of the menopause. After the age of 60 years, HRT should not be initiated unless 
there is a compelling indication. For those with premature menopause, HRT should be 
recommended and started as soon as possible.  
 
Tibolone, a tissue-specific compound, constitutes an alternative for treatment in 
postmenopausal women (Moore R. A. 1999). After oral intake, tibolone is rapidly 
converted into 2 estrogenic metabolites and its isomer, which has progestogenic and 
adrogenic activities (Lundstrom et al., 2002). As well as relieving vasomotor symptoms, 
tibolone has positive effects on sexual well-being and mood, and improves vaginal 
atrophy and urogenital symptoms. Prevention of bone loss is comparable to that seen 
with estrogen therapy and estrogen-progestrone therapy (Kenemans P. and Speroff L. 
2001). As tibolone rarely causes endometrial proliferation, no additional progesterone is 
needed. It also has good tolerability, being associated with a low incidence of vaginal 
bleeding and of breast pain (Kenemans P. and Speroff L. 2001). 
 
2.6.1 Hormone replacement therapy and breast cancer 
 
Controversies about the safety of different postmenopausal hormone therapies started 
30 years ago and reached a peak in 2003 after the publication of results from the 
Women Health Initiative (WHI) trial and the Million Women Study (MWS) (Topal et 
al., 2006). While there are contradictory findings, epidemiological data overall indicate 
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an increase in the risk of breast cancer during hormonal therapy (Soderqvist G. and 
Schoultz v. B. 2004). The pathophysiological mechanisms behind the association 
between risk and ongoing treatment are incompletely understood. 
 
The interpretation of available data is complicated by a lack of basic understanding as to 
how hormones work in the normal breast. HRT is not a uniform concept and a wide 
range of different estrogens and progestogens are available on the market and used at 
different doses, combinations and by different routes of administration. Estrogen is a 
well known mitogen in human breast epithelium but the action of progestogen is 
complex and incompletely understood (Soderqvist G. and Schoultz v. B.  2004). The 
basis of breast cancer risk associated with hormonal therapies may lie in the regulation 
of cell proliferation (Humphrey, L. L. et al., 2001). 
 
In the Million Women study in the UK, the relative risk of breast cancer between 
current HRT users and non-users was compared. Roughly one million women aged 50-
64 years participated in the study between 1996 and 2001. The result indicates that HRT 
is indeed associated with an increased risk of incident and fatal breast cancer especially 
for combined estrogen and progesterone therapy. Current users of HRT at recruitment 
were more likely than never users to develop breast cancer and die from it. However, 
past users of HRT were not an increased risk on incident of fatal disease. In current 
users, the risk of breast cancer increased with increasing total duration of use. Ten years 
use of HRT is estimated to result in five additional breast cancers per 1000 users of 
estrogen only preparation and 10 additional cancers per 1000 users of estrogen-
progestin combinations. The relative risk for breast cancer was 1.3 in users of estrogen 
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alone, 1.45 in tibolone users and 2.0 in women on oestrogen combined with progestin 
(Beral, 2003). 
 
A large meta-analysis was done in 1997 questioning a link between HRT and breast 
cancer risk which studied 51 epidemiological studies of 52,705 women with breast 
cancer and 108,411 women without breast cancer. This study found that the excess risk 
increases with the duration of use and disappears 5 years after stopping treatment 
(Colloborative Group in Hormonal Factors in Breast Cancer, 1997). A local study done 
in Kelantan by Norsa’adah et al found no significant association between HRT and 
breast cancer (Norsa’adah et al., 2005). The failure to detect the association may be 
related to the low uptake of HRT among post-menopausal women in Malaysia. 
 
2.7 Relationship between HRT and mammographic density 
 
Mammographic changes associated with hormone replacement therapy were first 
reported by Peck and Lowman in 1978 (Cyriak, D. 1993). These changes include a 
generalized increase in mammographic density, developing densities and enlarging 
benign masses such as cysts and fibroadenomas (Evans, A. 2001). It has been suggested 
that the use of estrogen alone may be associated with focal changes and the use of 
combination therapy with a diffuse increase in density HRT (Litherland, J. C. et a., 
2000). This can significantly adversely affect both the sensitivity and specificity of 
screening mammogram. According to (Erel et al., 1996) cessation of HRT resulted in 
regression of these mammographic findings. 
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Hormone replacement therapy (HRT) slows normal breast involution and causes an 
increase in mammographic density in women. The response of HRT depends on the 
individual woman and is neither necessarily uniform nor global. The increase in density 
is most commonly diffuse but may be focal or multifocal (Litherland, J. C. et al., 2000).  
It depends on the hormonal receptivity of the epithelial elements. There have been 
numerous studies done on the interplay between HRT and breast density which vary in 
quality and scope (Warren, G. 2004). Mammographically dense breasts reflect a high 
proportion of stromal, ductal and glandular tissue (Speroff, L. 2002). 
 
Various studies show that increase in breast density varies widely between 17% to 73%,  
depending on the method of assessment of changing density. However, when 
standardized, pre-agreed categories are used by reporters, figures fall in the range of 
17% - 24% indicating that the majority of HRT users do not have demonstrable change 
as a result of taking HRT (Litherland, J. C. 2000). The effect of endogenous and 
exogeneous hormones on the breast is a complex and so is the study of the effect of 
HRT on breast. The variety of drugs, drug dosage, drug combinations, routes of 
administration, duration of use, patient compliance, changes in drug type and dosage in 
long-term users , and the status of the breast at the time HRT is started contributes to the 
complexity. 
 
In clinical practice many different therapeutic regimens are used for hormonal 
replacement. The increase in mammographic density associated with HRT use varies 
according to the type of HRT preparation used (Evans, A. 2001). The type of treatment 
for hormone replacement depends on patient preference, compliance, conditions such as 
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previous hysterectomy allergy to transdermal preparations or gastrointestinal 
intolerance to oral preparations, besides the physician’s choice (Ozdemir  et al., 1999).  
 
Most studies show that combination hormones regimens increase mammographic 
density more often than estrogen only regimens (PEPI trial, 1999). Studies on breast 
morphology indicate that although the sites of their primary effects are somewhat 
different, both estrogen and progesterone stimulate breast cell division. However the 
mitotic rate of breast cells is higher during the luteal phase of the menstrual cycle than 
during the follicular phase, suggesting that progesterone and estrogen induce more 
mitoses than estrogen alone (Clarke C. L. and Sutherland R. L. 1990).   
 
Estrogen promotes growth of the ducts by causing proliferation and differentiation of 
mammary duct epithelium. Progesterone acts in synergism with estrogen on the distal 
portion of the ducts, favoring differentiation into acini, and promotes growth of 
lobuloalveolar structures. As ductal, periductal connective, and lobular tissue 
proliferates in response to a combination of estrogen and progesterone, the greatest 
increase in mammographic breast density would be expected in women being treated 
with the combination of estrogen and progesterone (Cyrlak and Wong, 1993). 
 
In 1990, Stomper et al reported that mammographic changes developed in 24% of 
postmenopausal women undergoing hormone replacement therapy. Changes were seen 
more often in women treated with the combination of estrogen and progesterone (26%( 
than in women treated with estrogen alone (17%). In another study done by (Berkowitz 
et al., 1990), 17% of women had mammographic changes while undergoing hormone 
replacement therapy. (Laya et al., 1995) showed that combined estrogen and 
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progesterone HRT resulted in a significant increase in the percentage of mammographic 
densities and change in parenchymal pattern in sizeable proportion of postmenopausal 
study subjects. After 1 year of treatment with continuous combined HRT in this study, 
there is upward shift of 24% in Wolfe classification and 73% increase in density 
percentage over baseline with magnitude of change of 10% or more over pretreatment 
values. This study also showed that density increase was most pronounced in those 
women with a lower baseline density (Laya et al., 1995).  
 
Another study done in 1999 at 7 Unites States centres involving 307 women showed 
significant increase in density within 1 year of use of combined preparation of HRT 
(Greendale et al., 1999). A prospective observational study done in Turkey showed that 
density changes are dependent of the HRT regimen and formation of cysts and solid 
lesions are not related to HRT (Ozdemir et al., 1999). Correlating with this is the 
findings of the Swedish study done by (Lundstrom et al., 1999) which showed that 
different preparations have different effects on breast density (Lundstrom et al., 1999). 
A 1998 consensus document concluded that the incidence of increased mammographic 
density was as much as twice as high with continuous combined HRT (up to 30%) 
compared with cyclic combined HRT (up to 15%) (Junkermann et al., 2004). 
 
A large scale study involving 1232 women was done in Ontario, Canada comparing 
HRT users and non-users. This study showed that density decreases after age 55 in non-
users of HRT, but not so in HRT users. In some women, density decrease continues on 
HRT suggesting they are refractory to the effect of hormone. Increased density was seen 
in less than 8% of women. They concluded that adverse effect may depend on 
receptivity of epithelial elements (Sterns and Zee, 2000). El-Bastawissi et al conducted 
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an observational study on 28984 HRT users and non-users which showed that HRT has 
transitory association with breast density (El-Bastawissi et al., 2001).  
 
A Swedish study done in 2002 showed the risk of density increase to be 10% for 
estradiol compounds and 28% for combined estradiol and progestin compounds. 
Increase in density is particularly common in women taking continuous combined 
preparations compared to women taking cyclical combined preparations. Several studies 
done show that different regimen have different effects on density, combination of 
estrogen-progesterone have more effect than other forms (Persson L., Thurfjell E. and 
Holmberg L. 1997, Lundstrom et al., 1999, Sendag et al., 2001, Erel et al., 2001, 
Lundstrom et al., 2002, Bulbul N. H., Ozden S. and Dayicioglu V. 2003, Vachon et al., 
2002, Greendale et al., 2001). Conjugated equine estrogens (CEE) alone did not affect 
mean mammographic percent density of women enrolled on the randomized, placebo 
controlled Postmenopausal Estrogen/Progestin Intervention (PEPI) trial. However, 
women who were randomly assigned to CEE/progestin combination treatment arms had 
mean increases in density that ranged from 3% to 5% (Greendale et al., 2001).  
 
Many large scale studies done across the globe show that HRT is associated with an 
increase in mammographic density in a significant portion of postmenopausal women. 
Several studies show that the increase occurs within the first year of use of starting HRT 
and diminishes within 3 weeks after stopping (Warren, R., 2004). According to 
(Marchesoni et al., 2006), the breast density increase quickly at the beginning of the 
hormonal therapy and decrease quickly at the end of the therapy (Marchesoni et al., 
2006).  Breast density change during HRT is dynamic, increasing with initiation and 
decreasing with discontinuation and change of therapy (Soderqvist G. and Schoultz v. 
